...home of the St. Johns Medical College Community

  • Increase font size
  • Default font size
  • Decrease font size
Home Articles Features Publication By Dr Jaideep Shenoi In Current Opnions In Oncology

Publication By Dr Jaideep Shenoi In Current Opnions In Oncology

E-mail Print PDF

Recent advances in novel radioimmunotherapeutic approaches

for allogeneic hematopoietic cell transplantation

Jaideep Shenoi, Ajay K. Gopal, Oliver W. Press and John M. Page




Purpose of review

Allogeneic hematopoietic cell transplantation (HCT) can be a curative treatment for

hematologic malignancies and over the last three decades, novel approaches have

resulted in significant reductions in morbidity and mortality. Despite current advances,

two major limitations remain: patients continue to die from recurrent disease, and rates

of nonrelapse mortality are relatively high due to regimen-related organ toxicities. The

ability to target therapy with radiolabeled antibodies provides an innovative way to

increase the tumoricidal dose of radiation to tumor sites, whereas sparing normal

organs, as further dose escalation of chemotherapy and radiotherapy in HCT

preparative regimens is not feasible due to dose-limiting toxicities.


Recent findings

This review discusses the most current allogeneic HCT data using radioimmunotherapy

(RIT) and focuses on recent trials involving patients at the highest risk for relapse. The

results from these studies have shown that standard-dose radiolabeled antibodies can

be safely combined with reduced-intensity preparative regimens with encouraging

results in a single institution phase II study.



Optimism remains that these RIT approaches will improve the cure rates of allogeneic

HCT for the thousands of patients with leukemias and lymphomas who undergo this

procedure each year.



allogeneic hematopoietic cell transplant, leukemia, lymphoma, radioimmunotherapy,

radiolabeled antibodies

Curr Opin Oncol 22:143–149

_ 2010

 The complete pdf  on

blog comments powered by Disqus